Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]
Status:
Unknown status
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
We are evaluating the incidence of significant hematological response, according to IWG
criteria including CR, PR or, major HI, (HI-E, Hl-N,or Hl- P), and cytogenetic response of
patients diagnosed with intermediate-2 or high-risk (International Prognostic Scoring System
[IPSS]) MDS with a deletion (del) 5q[31]